Ascent Group LLC Has $9.11 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Ascent Group LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 5.8% during the 3rd quarter, Holdings Channel reports. The fund owned 10,282 shares of the company’s stock after selling 635 shares during the period. Ascent Group LLC’s holdings in Eli Lilly and Company were worth $9,109,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Insight Wealth Strategies LLC bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $201,000. Lynx Investment Advisory bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. Harbor Capital Advisors Inc. increased its holdings in Eli Lilly and Company by 0.8% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 14,978 shares of the company’s stock worth $13,561,000 after purchasing an additional 119 shares in the last quarter. Olistico Wealth LLC raised its stake in shares of Eli Lilly and Company by 3.6% in the second quarter. Olistico Wealth LLC now owns 3,885 shares of the company’s stock worth $3,517,000 after purchasing an additional 135 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 53.0% in the second quarter. Kingswood Wealth Advisors LLC now owns 13,799 shares of the company’s stock valued at $12,494,000 after purchasing an additional 4,778 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Bank of America lowered their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Wolfe Research started coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

Shares of LLY opened at $795.35 on Monday. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The business has a 50-day moving average of $851.90 and a 200 day moving average of $870.85. The firm has a market cap of $755.04 billion, a P/E ratio of 85.98, a price-to-earnings-growth ratio of 3.01 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.